Evidence map›Paper›PMID 37653396›Full record

ArticleCancer & metabolism2023

Comparative polar and lipid plasma metabolomics differentiate KSHV infection and disease states.

Sara R Privatt, Camila Pereira Braga, Alicia Johnson, Salum J Lidenge, Luke Berry, John R Ngowi, Owen Ngalamika, Andrew G Chapple, Julius Mwaiselage, Charles Wood and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  4. Article
  5. Understanding Metabolic Pathway Rewiring by Oncogenic Gamma Herpesvirus.Journal of microbiology and biotechnology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Sara R PrivattSchool of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA.
Camila Pereira BragaDepartment of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.
Alicia JohnsonDepartment of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.
Salum J LidengeOcean Road Cancer Institute, Dar Es Salaam, Tanzania.
Luke BerryDepartment of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE, USA.
John R NgowiOcean Road Cancer Institute, Dar Es Salaam, Tanzania.
Owen NgalamikaDermatology and Venereology Section, Adult Hospital of the University Teaching Hospitals, University of Zambia School of Medicine, Lusaka, Zambia.
Andrew G ChappleDepartment of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Julius MwaiselageOcean Road Cancer Institute, Dar Es Salaam, Tanzania.
Charles WoodSchool of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA.
John T WestDepartment of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA. jwest6@lsuhsc.edu.
Jiri AdamecDepartment of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA, USA. jadame@lsuhsc.edu.
University of Nebraska–Lincoln · USLouisiana State University Health Sciences Center New Orleans · USMuhimbili University of Health and Allied Sciences · TZOcean Road Cancer Institute · TZUniversity Teaching Hospital · ZM

Funding

KSHV,HIV and the Kaposi's Sarcoma Tumor NicheR01CA228178 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WEST, JOHN T., WOOD, CHARLES · 2018 to 2024
$2.9M
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"K43TW011418 · FIC · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI LIDENGE, SALUM JUMA · 2019 to 2023
$741k
FIC NIH HHS K43 TW011418NCI NIH HHS R01 CA228178
6 · The paper itself

Abstract

backgroundKaposi sarcoma (KS) is a neoplastic disease etiologically associated with infection by the Kaposi sarcoma-associated herpesvirus (KSHV). KS manifests primarily as cutaneous lesions in individuals due to either age (classical KS), HIV infection (epidemic KS), or tissue rejection preventatives in transplantation (iatrogenic KS) but can also occur in individuals, predominantly in sub-Saharan Africa (SSA), lacking any obvious immune suppression (endemic KS). The high endemicity of KSHV and human immunodeficiency virus-1 (HIV) co-infection in Africa results in KS being one of the top 5 cancers there. As with most viral cancers, infection with KSHV alone is insufficient to induce tumorigenesis. Indeed, KSHV infection of primary human endothelial cell cultures, even at high levels, is rarely associated with long-term culture, transformation, or growth deregulation, yet infection in vivo is sustained for life. Investigations of immune mediators that distinguish KSHV infection, KSHV/HIV co-infection, and symptomatic KS disease have yet to reveal consistent correlates of protection against or progression to KS. In addition to viral infection, it is plausible that pathogenesis also requires an immunological and metabolic environment permissive to the abnormal endothelial cell growth evident in KS tumors. In this study, we explored whether plasma metabolomes could differentiate asymptomatic KSHV-infected individuals with or without HIV co-infection and symptomatic KS from each other.

methodsTo investigate how metabolic changes may correlate with co-infections and tumorigenesis, plasma samples derived from KSHV seropositive sub-Saharan African subjects in three groups, (A) asymptomatic (lacking neoplastic disease) with KSHV infection only, (B) asymptomatic co-infected with KSHV and HIV, and (C) symptomatic with clinically diagnosed KS, were subjected to analysis of lipid and polar metabolite profiles

resultsPolar and nonpolar plasma metabolic differentials were evident in both comparisons. Integration of the metabolic findings with our previously reported KS transcriptomics data suggests dysregulation of amino acid/urea cycle and purine metabolic pathways, in concert with viral infection in KS disease progression.

conclusionsThis study is, to our knowledge, the first to report human plasma metabolic differentials between in vivo KSHV infection and co-infection with HIV, as well as differentials between co-infection and epidemic KS.

Indexed as

BiomarkersHIVKaposi sarcomaKSHVMetabolite profilingMetabolomics

Identifiers

PMID37653396
PMCPMC10470137
OpenAlexW4386329415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.